This is a preview of subscription content, log in via an institution to check access.
Notes
2020 US dollars
Reference
Reifsnider OS, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Research and Care : 3 May 2021. Available from: URL: http://dx.doi.org/10.1136/bmjdrc-2020-001313
Rights and permissions
About this article
Cite this article
Empagliflozin cost effective in patients with T2DM and CVD. PharmacoEcon Outcomes News 878, 11 (2021). https://doi.org/10.1007/s40274-021-7697-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7697-9